EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC 4.0

Image-guided moderately hypofractionated proton beam therapy for localized prostate cancer: 5-year outcomes of a phase II trial

Takashi Iizumi iD, Hitoshi Ishikawa iD, Yuta Sekino, Motohiro Murakami, Keiichi Tanaka, Daichi Takizawa, Hirokazu Makishima, Yutaro Mori, Satoshi Kamizawa, Masashi Mizumoto iD, Toshiyuki Okumura, Hiroyoshi Suzuki und 2 weitere

Journal of Radiation Research · 2026

DOI: 10.1093/jrr/rrag051 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Radiation Research, 2026. Verfasst von Takashi Iizumi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8576, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Proton Therapy, Radiation Dose Hypofractionation, Radiotherapy, Image-Guided. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: JSPS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The purpose of the present study is to confirm the efficacy and feasibility of moderately hypofractionated proton beam therapy (PBT) at a total dose of 63 Gy relative biological effectiveness (RBE) in 21 fractions for prostate cancer. This phase II clinical trial (PPS-002: UMIN 000017679) enrolled 125 men with histologically confirmed prostate cancer (cT1c-3aN0M0). The primary endpoint was grade ≥2 late gastrointestinal (GI) toxicities. Secondary endpoints included biochemical recurrence rates, clinical recurrence rates, overall survival (OS) and acute toxicities and late genitourinary (GU) toxicities. With a median follow-up period of 71.0 months (IQR: 60–84), the 5-year cumulative incidences of late grade 2 or higher GI and GU adverse events (AEs) were 3.3% and 8.1%, respectively. Biochemical recurrences were observed in three patients; no clinical recurrences occurred. The 5-year biochemical recurrence-free, clinical recurrence-free and OS rates were 97.6% (95% CI: 94.9–100.0), 100% and 97.5% (95% CI: 94.8–100.0), respectively. The long-term follow-up results of moderately hypofractionated PBT of 63 Gy (RBE) in 21 fractions confirmed low incidences of late AEs, successfully meeting the primary endpoint. Furthermore, the low incidence of tumor recurrence supports the overall safety and feasibility of this fractionation schedule.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProton TherapyRadiation Dose HypofractionationRadiotherapy, Image-GuidedMaleHumansAgedTreatment OutcomeMiddle AgedDose Fractionation, RadiationNeoplasm Recurrence, LocalAged, 80 and over

Stichwörter der Autor:innen

hypofractionationlate toxicityprospective studyprostate cancerproton beam therapy

Autor:innen und Institutionen

  • Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8576, Japan.
  • QST Hospital, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba, Chiba 263-8555, Japan.
  • Department of Radiation Oncology, Ibaraki Prefectural Central Hospital, Ibaraki Cancer Center, 6528 Koibuchi, Kasama, Ibaraki 309-1793, Japan.
  • Department of Radiation Oncology, Tsuchiura Kyodo General Hospital, 4-1-1, Otsuno, Tsuchiura, Ibaraki 300-0028, Japan.
  • Department of Radiation Oncology, Hitachi General Hospital, Hitachi Ltd., 2-1-1 Jonancho, Hitachi, Ibaraki 317-0077, Japan.
  • Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura, Chiba 263-8555, Japan.

ORCID-Profile: Takashi Iizumi, Hitoshi Ishikawa, Masashi Mizumoto, Hideyuki Sakurai

Förderung

  • JSPS

Zitieren

APA

Iizumi, T., Ishikawa, H., Sekino, Y., Murakami, M., Tanaka, K., Takizawa, D., Makishima, H., Mori, Y., Kamizawa, S., Mizumoto, M., Okumura, T., Suzuki, H., Nishiyama, H., & Sakurai, H. (2026). Image-guided moderately hypofractionated proton beam therapy for localized prostate cancer: 5-year outcomes of a phase II trial. Journal of Radiation Research. https://doi.org/10.1093/jrr/rrag051

Vancouver

Iizumi T, Ishikawa H, Sekino Y, Murakami M, Tanaka K, Takizawa D, et al. Image-guided moderately hypofractionated proton beam therapy for localized prostate cancer: 5-year outcomes of a phase II trial. Journal of Radiation Research. 2026. doi:10.1093/jrr/rrag051

BibTeX
@article{Iizumi2026,
  author = {Iizumi, Takashi and Ishikawa, Hitoshi and Sekino, Yuta and Murakami, Motohiro and Tanaka, Keiichi and Takizawa, Daichi and Makishima, Hirokazu and Mori, Yutaro and Kamizawa, Satoshi and Mizumoto, Masashi and Okumura, Toshiyuki and Suzuki, Hiroyoshi and Nishiyama, Hiroyuki and Sakurai, Hideyuki},
  title = {Image-guided moderately hypofractionated proton beam therapy for localized prostate cancer: 5-year outcomes of a phase II trial},
  journal = {Journal of Radiation Research},
  year = {2026},
  doi = {10.1093/jrr/rrag051}
}
Kostenlos starten →